白蛋白结合型紫杉醇在复发性小细胞肺癌二线治疗中的临床效果分析  

Clinical Efficacy of Albumin-bound Paclitaxel in the Second-line Treatment of Recurrent Small Cell Lung Cancer

作　　者：梁峰 朱铁年 张怡梅 刘建坤 LIANG Feng;ZHU Tienian;ZHANG Yimei;LIU Jiankun(Department of Oncology,the 980 Hospital of the Joint Service Support Force of the Chinese PLA,Shijiazhuang 050082,China)

机构地区：[1]解放军联勤保障部队第九八〇医院肿瘤内科,石家庄050082

出　　处：《临床误诊误治》2023年第6期39-43,共5页Clinical Misdiagnosis & Mistherapy

基　　金：河北省2021年度医学科学研究课题(20211219);河北省科学技术厅项目(H2021505008)。

摘　　要：目的 观察以白蛋白结合型紫杉醇为基础的二线化疗方案治疗复发性小细胞肺癌(SCLC)的临床效果及安全性。方法 选择2016年1月—2021年12月收治的复发性SCLC 50例,接受白蛋白结合型紫杉醇单药治疗27例,白蛋白结合型紫杉醇联合其他药物治疗23例。所有患者化疗2个周期后评价疗效,观察毒副作用发生情况。结果 50例复发性SCLC患者客观缓解率为24.0%,疾病控制率为48.0%,中位无进展生存时间为5.7个月。毒副作用主要为1~2级,均可耐受。化疗周期数≤3个的复发性SCLC患者白细胞减少和中性粒细胞减少的发生率低于化疗周期>3个患者(P<0.05)。单独用药复发性SCLC患者乏力发生率低于联合用药患者(P<0.05)。ECOG评分<2分复发性SCLC患者血红蛋白减少和发热发生率低于ECOG评分≥2分患者(P<0.05)。结论 白蛋白结合型紫杉醇为基础的二线化疗方案治疗复发性SCLC效果肯定,毒副作用可耐受,安全性较高。Objective To observe the clinical efficacy and safety of albumin-bound paclitaxel-based second-line chemotherapy regimen for recurrent small cell lung cancer(SCLC).Methods Fifty patients with recurrent SCLC treated from January 2016 to December 2021 were selected.Of them,27 patients received albumin-bound paclitaxel monotherapy and 23 patients received albumin-bound paclitaxel combined with other drugs.The efficacy of all patients were evaluated after 2 cycles of chemotherapy,and the occurrence of toxic and side effects was observed.Results The objective response rate of 50 patients with recurrent SCLC was 24.0%,the disease control rate was 48.0%,and the median progression-free survival time was 5.7 months.The main toxic and side effects were at stage 1-2,which could be tolerated.The incidence of leukopenia and neutropenia in recurrent SCLC patients with chemotherapy cycles≤3 was lower than that in patients with chemotherapy cycles>3(P<0.05).The incidence of fatigue in patients with recurrent SCLC treated with one drug alone was lower than that in patients with SCLC treated with drugs in combination(P<0.05).The incidence of decreased hemoglobin and fever in SCLC patients with ECOG score<2 was lower than that in patients with ECOG score≥2(P<0.05).Conclusion The second-line chemotherapy regimen based on albumin-bound paclitaxel has a positive effect in the treatment of recurrent SCLC,with tolerable toxic and side effects and better safety.

关 键 词：小细胞肺癌 白蛋白结合型紫杉醇 无进展生存期 骨髓抑制 白细胞减少 中性粒细胞减少 血红蛋白减少 药物毒性 

分 类 号：R734.2[医药卫生—肿瘤]